These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23685212)

  • 21. Influence of the DNA sequence/length and pH on deaminase activity, as well as the roles of the amino acid residues around the catalytic center of APOBEC3F.
    Wan L; Nagata T; Katahira M
    Phys Chem Chem Phys; 2018 Jan; 20(5):3109-3117. PubMed ID: 28825755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.
    Shaban NM; Shi K; Li M; Aihara H; Harris RS
    J Mol Biol; 2016 Jun; 428(11):2307-2316. PubMed ID: 27139641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of HIV-1 Vif regions required for CBF-β interaction and APOBEC3 suppression.
    Wang H; Liu B; Liu X; Li Z; Yu XF; Zhang W
    PLoS One; 2014; 9(5):e95738. PubMed ID: 24810617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.
    Wissing S; Galloway NL; Greene WC
    Mol Aspects Med; 2010 Oct; 31(5):383-97. PubMed ID: 20538015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
    Richards C; Albin JS; Demir Ö; Shaban NM; Luengas EM; Land AM; Anderson BD; Holten JR; Anderson JS; Harki DA; Amaro RE; Harris RS
    Cell Rep; 2015 Dec; 13(9):1781-8. PubMed ID: 26628363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
    Pery E; Rajendran KS; Brazier AJ; Gabuzda D
    J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
    Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
    Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.
    Chen G; He Z; Wang T; Xu R; Yu XF
    J Virol; 2009 Sep; 83(17):8674-82. PubMed ID: 19535450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.
    Cadima-Couto I; Saraiva N; Santos AC; Goncalves J
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):296-307. PubMed ID: 21279453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOBEC3F determinants of HIV-1 Vif sensitivity.
    Land AM; Shaban NM; Evans L; Hultquist JF; Albin JS; Harris RS
    J Virol; 2014 Nov; 88(21):12923-7. PubMed ID: 25142588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif.
    Shandilya SM; Bohn MF; Schiffer CA
    Virology; 2014 Dec; 471-473():105-16. PubMed ID: 25461536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.
    Lassen KG; Wissing S; Lobritz MA; Santiago M; Greene WC
    J Biol Chem; 2010 Sep; 285(38):29326-35. PubMed ID: 20624919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
    Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
    Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
    Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
    J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
    Albin JS; Harris RS
    Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
    J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
    Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
    J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.